SCHEMBL19633771

SCHEMBL19633771

Cc1ccc(-c2cc(=O)cc3oc4cc(O)ccc4cc2-3)c(C(=O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 8/20 0.48
USP2 O75604 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
POLB P06746 3/20 0.43
ALPL P05186 1/20 0.43
ALPI P09923 1/20 0.43
ALPG P10696 1/20 0.43
KDM4E B2RXH2 3/20 0.42
GLA P06280 3/20 0.42
GAA P10253 3/20 0.42
MAPT P10636 3/20 0.42
S1PR4 O95977 1/20 0.42
S1PR1 P21453 1/20 0.42
HSD17B3 P37058 1/20 0.42
NPC1 O15118 2/20 0.41
ESR2 Q92731 1/20 0.40
PFKFB3 Q16875 1/20 0.40
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656903 0.84 USP2 (0.52) MIFUSP2L3MBTL1MEN1KMT2A
SCHEMBL10098714 0.77 USP2 (0.76) USP2L3MBTL1MEN1KMT2APOLB
SCHEMBL12045940 0.72 USP2 (0.68) USP2L3MBTL1MEN1KMT2APOLB
SCHEMBL16137357 0.72 MAOB (0.52) MEN1KMT2APOLBKDM4ENPC1
SCHEMBL4621112 0.69 CSNK2A1 (0.65) MEN1KMT2APOLBKDM4EGAA
SCHEMBL12900563 0.68 USP2 (0.72) USP2L3MBTL1MEN1KMT2APOLB
SCHEMBL13015010 0.67 SOS1 (0.74) USP2L3MBTL1MEN1KMT2APOLB
SCHEMBL37883 0.67 MAOA (0.76) MIFMEN1KMT2AKDM4EGLA
SCHEMBL5656898 0.66 TYR (0.56) MIFMEN1KMT2AKDM4EGLA
SCHEMBL8427558 0.66 USP2 (0.64) USP2L3MBTL1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170333576-A1 NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY THE JOHNS HOPKINS UNIVERSITY (US) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333576-A1 NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY FOLH1, PSMA3, PSMA7 MIF 2735/4885USP2 400/4885L3MBTL1 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.